H. Findlow

Gregory A. Price, B. Plikaytis, G. Carlone, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008

B. Gessner, R. Borrow, S. Diagbouga, 2013, PloS one.

Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination.

R. Read, J. Wing, Lynne Smart, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

N. Andrews, E. Miller, P. Waight, 2009, Clinical and Vaccine Immunology.

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.

N. Andrews, D. Goldblatt, M. Snape, 2021, The Lancet. Infectious diseases.

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.

A. Pollard, Ushma Galal, M. Snape, 2020, Open forum infectious diseases.

The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine

J. Gomis, N. Basta, D. Chandramohan, 2015, The Journal of infectious diseases.

Prospective survey on carriage of Neisseria meningitidis and protective immunity to meningococci in schoolchildren in Niamey (Niger): focus on serogroup W135.

S. Chanteau, P. Boisier, A. Garba, 2006, Microbes and infection.

Immunogenicity and Safety of a Meningococcal Serogroup A, C, Y and W Glycoconjugate Vaccine, ACWY-TT

R. Borrow, H. Findlow, 2013, Advances in Therapy.

Meningococcal carriage and immunity in western Burkina Faso, 2003.

B. Gessner, R. Borrow, L. Sangaré, 2007, Vaccine.

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali

N. Basta, R. Borrow, S. Sow, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.

R. Booy, R. Borrow, H. Rashid, 2018, Vaccine.

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study

T. Vesikari, R. Borrow, M. S. Dhingra, 2020, Human vaccines & immunotherapeutics.

Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine.

R. Borrow, Y. Al-Mazrou, P. Oster, 2014, Vaccine.

Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16

N. Andrews, S. Ladhani, E. Linley, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction

M. Ramsay, J. Findlow, R. Borrow, 2012, Clinical and Vaccine Immunology.

Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine

E. Miller, P. Waight, J. Findlow, 2014, Journal of Occupational Medicine and Toxicology.

Immunogenicity of a Single Dose of Meningococcal Group C Conjugate Vaccine Given at 3 Months of Age to Healthy Infants in the United Kingdom

N. Andrews, D. Goldblatt, E. Miller, 2012, The Pediatric infectious disease journal.

Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom

N. Andrews, E. Miller, P. Waight, 2008, Clinical and Vaccine Immunology.

Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with a 7-valent pneumococcal conjugate vaccine and a combination DTaP5/Hib /IPV vaccine in healthy UK infants

N. Andrews, E. Miller, P. Waight, 2008 .

Investigation of Different Group A Immunoassays following One Dose of Meningococcal Group A Conjugate Vaccine or A/C Polysaccharide Vaccine in Adults

B. Plikaytis, G. Carlone, E. Marchetti, 2009, Clinical and Vaccine Immunology.

Serum Antibody Kinetics following Nasal or Parenteral Challenge with Meningococcal Polysaccharide in Healthy Adults

R. Read, P. Hardelid, E. Miller, 2011, Clinical and Vaccine Immunology.

Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age

N. Andrews, D. Goldblatt, E. Miller, 2010, Clinical and Vaccine Immunology.

Investigation of correlates of protection against pharyngeal carriage of Neisseria meningitidis genogroups W and Y in the African meningitis belt

B. Greenwood, C. Sokhna, L. Cooper, 2017, PloS one.

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years

R. Adegbola, Yuxiao Tang, B. Plikaytis, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience

R. Borrow, H. Findlow, 2016, Pediatric Drugs.

Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age

N. Andrews, E. Miller, P. Waight, 2015, The Pediatric infectious disease journal.

Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?

R. Borrow, H. Findlow, 2015, Human vaccines & immunotherapeutics.

polysaccharide in healthy adults.

P. Hardelid, R. Borrow, E. Kaczmarski, 2011 .

Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.

R. Borrow, L. Weckx, M. A. Sáfadi, 2016, Vaccine.

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination

B. Plikaytis, G. Carlone, R. Borrow, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.

N. Andrews, D. Goldblatt, S. Ladhani, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.

N. Gogtay, U. Thatte, B. Plikaytis, 2007, Vaccine.

Safety and Immunogenicity of a Meningococcal Quadrivalent Conjugate Vaccine in Five- to Eight-Year-Old Saudi Arabian Children Previously Vaccinated with Two Doses of a Meningococcal Quadrivalent Polysaccharide Vaccine

David R. Johnson, R. Borrow, Y. Al-Mazrou, 2012, Clinical and Vaccine Immunology.

Interactions of conjugate vaccines and co-administered vaccines

R. Borrow, H. Findlow, 2016, Human vaccines & immunotherapeutics.

The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.

B. Plikaytis, G. Carlone, M. Ota, 2014, Vaccine.

Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?

J. Ouédraogo, B. Gessner, N. Meda, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunogenicity and Safety of a Meningococcal Quadrivalent Conjugate Vaccine in Saudi Arabian Adolescents Previously Vaccinated with One Dose of Bivalent and Quadrivalent Meningococcal Polysaccharide Vaccines: a Phase III, Controlled, Randomized, and Modified Blind-Observer Study

David R. Johnson, R. Borrow, Y. Al-Mazrou, 2012, Clinical and Vaccine Immunology.

Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood

A. Pollard, M. Snape, H. Robinson, 2011, Clinical and Vaccine Immunology.

Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: evidence for increased levels of serum bactericidal antibodies.

G. Jönsson, R. Borrow, Xilian Bai, 2015, Vaccine.

Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection.

S. Ladhani, R. Borrow, K. Townsend, 2014, Vaccine.

Competitive Inhibition Flow Analysis Assay for the Non-Culture-Based Detection and Serotyping of Pneumococcal Capsular Polysaccharide

R. Borrow, P. Balmer, C. Broughton, 2008, Clinical and Vaccine Immunology.

Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.

Z. Memish, A. Assiri, M. Almasri, 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

D. Diop, R. Adegbola, Yuxiao Tang, 2011, The New England journal of medicine.

Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

R. Adegbola, Yuxiao Tang, B. Plikaytis, 2015, Clinical Infectious Diseases.

Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.

N. Andrews, D. Goldblatt, S. Ladhani, 2015, Vaccine.

Meningococcal Group C and W135 Immunological Hyporesponsiveness in African Toddlers

R. Adegbola, Yuxiao Tang, E. Marchetti, 2011, Clinical and Vaccine Immunology.

Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007.

A. Pollard, C. Dold, R. Borrow, 2018, Vaccine.

Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.

Yuxiao Tang, B. Plikaytis, S. Juvekar, 2012, Vaccine.